ASX Linkedin Twitter               

 

Dr Malcolm McColl
Managing Director and Chief Executive Officer

Dr. McColl has more than 20 years’ management experience in the pharmaceutical and biotechnology industries, serving in senior level business development positions at both international and regional companies, with a focus on the oncology field.

Prior to joining Viralytics in 2013, he was Vice President Business Development at Starpharma, where he led partnering activities and programs. From 2007 to 2010, he served as Director of Business Development for global healthcare company, Hospira (formerly Mayne Pharma and acquired by Pfizer in 2015), where he was responsible for Europe, The Middle East and Africa. In this UK-based position, he led negotiations for licensing and acquisition transactions primarily in the oncology field. Previously, he was Hospira’s Director of Business Development for the Asia/Pacific region, completing multiple partnering transactions and contributing to strong revenue growth in the region.

Dr. McColl also spent 13 years at CSL, a global specialty biotherapeutics company, culminating in his US-based role as Global Vice President, Business Development for the Animal Health Division. In this position, he played a lead role in the strategic development and globalisation of the Animal Health business, including entry into the US market. Dr. McColl holds a first class honors degree in Veterinary Science from Melbourne University and an MBA from the Melbourne Business School.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).